Zur Kurzanzeige

2019-12-10Zeitschriftenartikel DOI: 10.25646/6616
Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18)
dc.contributor.authorKissling, Esther
dc.contributor.authorPozo, Francisco
dc.contributor.authorBuda, Silke
dc.contributor.authorVilcu, Ana-Maria
dc.contributor.authorRizzo, Caterina
dc.contributor.authorGherasim, Alin
dc.contributor.authorHorváth, Judit Krisztina
dc.contributor.authorBrytting, Mia
dc.contributor.authorDomegan, Lisa
dc.contributor.authorMeijer, Adam
dc.contributor.authorParadowska-Stankiewicz, Iwona
dc.contributor.authorMachado, Ausenda
dc.contributor.authorVišekruna Vučina, Vesna
dc.contributor.authorLazar, Mihaela
dc.contributor.authorJohansen, Kari
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorvan der Werf, Sylvie
dc.contributor.authorBella, Antonino
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorFerenczi, Annamária
dc.contributor.authorZakikhany, Katherina
dc.contributor.authorO'Donnell, Joan
dc.contributor.authorDijkstra, Frederika
dc.contributor.authorBogusz, Joanna
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorKurečić Filipović, Sanja
dc.contributor.authorPitigoi, Daniela
dc.contributor.authorPenttinen, Pasi
dc.contributor.authorValenciano, Marta
dc.contributor.authorI-MOVE/I-MOVE+ study team
dc.date.accessioned2020-03-30T07:41:42Z
dc.date.available2020-03-30T07:41:42Z
dc.date.issued2019-12-10none
dc.identifier.other10.1016/j.jvacx.2019.100042
dc.identifier.urihttp://edoc.rki.de/176904/6576
dc.description.abstractIntroduction Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons; while the A(H1N1)pdm09 component changed in 2017–18. In both seasons, vaccine seed A(H3N2) viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity. Methods We used the test-negative design in a multicentre primary care case-control study in 12 European countries to measure 2016–17 and 2017–18 influenza vaccine effectiveness (VE) against laboratory-confirmed influenza A(H1N1)pdm09 and A(H3N2) overall and by age group. Results During the 2017–18 season, the overall VE against influenza A(H1N1)pdm09 was 59% (95% CI: 47–69). Among those aged 0–14, 15–64 and ≥65 years, VE against A(H1N1)pdm09 was 64% (95% CI: 37–79), 50% (95% CI: 28–66) and 66% (95% CI: 42–80), respectively. Overall VE against influenza A(H3N2) was 28% (95% CI: 17–38) in 2016–17 and 13% (95% CI: −15 to 34) in 2017–18. Among 0–14-year-olds VE against A(H3N2) was 28% (95%CI: −10 to 53) and 29% (95% CI: −87 to 73), among 15–64-year-olds 34% (95% CI: 18–46) and 33% (95% CI: −3 to 56) and among those aged ≥65 years 15% (95% CI: −10 to 34) and −9% (95% CI: −74 to 32) in 2016–17 and 2017–18, respectively. Conclusions Our study suggests the new A(H1N1)pdm09 vaccine component conferred good protection against circulating strains, while VE against A(H3N2) was <35% in 2016–17 and 2017–18. The egg propagation derived antigenic mismatch of the vaccine seed virus with circulating strains may have contributed to this low effectiveness. A(H3N2) seed viruses for vaccines in subsequent seasons may be subject to the same adaptations; in years with lower than expected VE, recommendations of preventive measures other than vaccination should be given in a timely manner.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectInfluenzaeng
dc.subjectInfluenza vaccineeng
dc.subjectVaccine effectivenesseng
dc.subjectmulticentre studyeng
dc.subjectCase-control studyeng
dc.subjectEuropeeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleEffectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18)none
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6576-1
dc.identifier.doihttp://dx.doi.org/10.25646/6616
dc.type.versionpublishedVersionnone
local.edoc.container-titleVaccine: Xnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.sciencedirect.com/science/article/pii/S2590136219300439none
local.edoc.container-publisher-nameElseviernone
local.edoc.container-volume3none
local.edoc.container-issue100042none
local.edoc.container-year2019none
local.edoc.container-firstpage1none
local.edoc.container-lastpage10none
local.edoc.rki-departmentInfektionsepidemiologienone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige